We use cookies to personalize your experience, track visits, and analyze traffic. Learn more.

Finish up. Get your offer!

Want full access to all recordings, Q&A with the experts, and community?

Unlock the full summit experience by upgrading to an All Access Pass!

👉🏼 Your Free Live Pass is only valid on Nov 21-23

Can’t watch all 50+ interviews? Upgrade for on-demand access👇🏼

Claim your limited-time offer

Community
All Access Pass

Perfect for general attendees seeking full summit access at the lowest possible rate.

🎥 All session recordings
💬 Live panels with experts
🌍 Community & networking
📚 Lived experience resources
🔊 Audio downloads & transcripts
📖 Implementation guide document
🎁 Exclusive partner perks and more

$67 USD Save $80

Regular price: $147

UPGRADE NOW

Professional
All Access Pass

Designed for therapists, physicians, researchers, coaches, & practitioners.

🎟 Everything in the Community Pass
👨🏼‍🏫 Private workshop on lived experience
🎓 Early access to training: Lived Experience in MDMA Therapy for PTSD

Your purchase supports our nonprofit mission and funds peer support.

$97 USD Save $100

Regular price: $197

UPGRADE NOW

To pay, use the same email you registered with for the Free Live Pass.

Lock in the best deal now!

This is a grassroots effort, no sponsors, no grants, no outside influence, just real stories, deep insights, and healing wisdom. As we grow, so do our costs.

	Community Pass	Professional Pass
After Oct 1	$97	$137
After Nov 1	$127	$177
After Nov 21	$147	$197

Upgrade to an All Access Pass and receive:

🎥 All session recordings: Rewatch all expert interviews anytime, at your own pace.

💬 Live panel discussions: Connect directly with experts and ask your questions live.

💻 Networking sessions: Join breakout rooms and connect with the summit community.

🌍 Community platform access: Be the first to join our upcoming membership space.

🎧 Audio downloads: Listen anytime, anywhere—perfect for learning on the go.

📝 Transcripts & summaries: Get key takeaways without rewatching every session.

📖 Implementation guide: A step-by-step document on applying key summit insights.

📚 Curated resource library: Books, media, and research papers on lived experience.

🎁 Exclusive partner perks: Special offers and discounts from our trusted partners.

Professional All Access Pass Bonus

Join a dedicated lived experience workshop and be among the first to access our upcoming training: Lived Experience in MDMA Therapy for PTSD.

All Access Pass is a complete learning and networking package in psychedelic care

You’ve already claimed your Free Live Pass, but to truly absorb and apply these insights, ongoing access is key. Unlock the full summit experience by upgrading to an All Access Pass!

This isn’t just a “replay” pass, it’s a toolkit designed for advancement and growth in psychedelic research, treatment, and policy. Get yours now.

Whether you want to enhance your therapeutic skills, stay at the forefront of research, or connect with like-minded individuals, the All Access Pass gives you ongoing access to everything the summit has to offer. Take the next step in your journey now!

Attend live panel discussions with leading experts

During and after the summit, with an All Access Pass you'll join insightful Q&A panels on critical topics with seasoned psychedelic experts. Ask your questions live and gain valuable perspectives. Sports are limited for these panels, upgrade today!

Expert Q&A Panel #1
Centering Lived Experience in Psychedelic Research, Training, and Care

What happens when lived expertise guides the future of care? Join experts Michael Mithoefer, MD, Janis Phelps, PhD, Joost Breeksema, PhD, Pamela Kryskow, MD, and Pedram Dara for a live panel exploring how lived experience can reshape they way we research, train, and deliver psychedelic therapy.

Expert Q&A Panel #2
MDMA-assisted Therapy: Lived Insights, Challenges, and What’s Left Unsaid

Hear directly from individuals who have undergone MDMA therapy through global clinical trials and Canada’s Special Access Program. This live panel will explore what the manuals don’t cover, from breakthroughs to blind spots. A deeper, more nuanced look at MDMA-assisted therapy in real life and how to advance the treatment.

Expert Q&A Panel #3
Inside Psychedelic Clinical Trials: What Participants Want You to Know

Beyond the data: explore the unique perspectives of research participants from psychedelic clinical trials with DMT, Psilocybin, and MDMA for depression, generalized anxiety disorder, and PTSD. They will speak candidly about the process, the impact, and the emotional terrain that often gets overlooked in the official narrative.

Expert Q&A Panel #4
Lived Experience as Expertise: A Paradigm Shift in Psychedelic Healthcare

Can people with lived experience get trained and certified? Meet the emerging leaders from inside and outside the psychedelic field using their lived expertise to inform, guide, and transform how healthcare is designed and delivered.

Expert Q&A Panel #5
Beyond Treatment: Integration, Lingering Effects, and the Need for Aftercare

Healing doesn’t end after the final dose and its following integration sessions. This live panel dives into integration, unexpected symptoms, and the long arc of recovery, and where support often falls short.

Expert Q&A Panel #6
Rethinking Psychedelic Evidence: Real-World Outcomes and Lived Truths

Randomized Clinical Trials aren’t the whole story. Learn how lived experience and real-world outcomes can deepen, challenge, or expand the evidence base for how we approach psychedelic care.

Expert Q&A Panel #7
What Really Heals? Psychotherapy, Placebo, and the Role of the Drug

Is it the molecule, the meaning, or the relationship? A nuanced exploration of healing mechanisms in psychedelic therapy, what we know, what we assume, and what we miss.

Expert Q&A Panel #8
Safety, Risk, and Ethics in Psychedelic Healing: Accountability and Gaps

Psychedelics aren’t risk-free. This panel confronts ethical blind spots, safety concerns, and the need for accountability in an accelerating field.

Expert Q&A Panel #9
Ibogaine and Veterans: Lived Experiences of Healing Trauma and Addiction

Veterans who turned to ibogaine share powerful, complex stories of healing. This panel goes beyond headlines to explore what’s really at stake and what’s possible.

Expert Q&A Panel #10
Psychedelics and End-of-Life Distress: Medicine, Meaning, and Mortality

Facing death changes everything. Hear from those using psychedelics in palliative care to confront fear, find peace, and reframe what it means to live and die well.

Here's everything you get with the All Access Pass

Unlock the full summit experience today!

Get the lowest price as an early supporter before our operational costs rise with more attendees. With no sponsorship funding, all expenses for support, platform, and fees come out of pocket. That’s why the best deal is always right now. Upgrade today!

Community
All Access Pass

Perfect for general attendees seeking full summit access at the lowest possible rate.

$67 USD Save $80

Regular price: $147

UPGRADE NOW

Professional
All Access Pass

Designed for therapists, physicians, researchers, coaches, & practitioners.

$97 USD Save $100

Regular price: $197

UPGRADE NOW

To pay, use the same email you registered with for the Free Live Pass.

Support a nonprofit mission

Upgrading to All Access Pass helps launch the

Psychedelic Lived Experiences Association (PLEA)

a new nonprofit advancing lived experience in

psychedelic research, treatment, and policy.

Need a scholarship?

We believe cost shouldn’t be a barrier to participation. A limited number of partial and full scholarships are available for attendees from lower-income regions, students, and those in financial need. Apply below to request one.

APPLY NOW

Get $500+ worth of value with an All Access Pass

	Free Live Pass	All Access Pass
Live access to all 3 summit days	✅	✅
On-demand access to all recordings	❌	✅
Live Q&A panels with summit experts	❌	✅
Networking sessions & breakout rooms	❌	✅
Community platform early access	❌	✅
Audio edition of the entire summit	❌	✅
Transcripts & summaries of all sessions	❌	✅
Implementation guide document	❌	✅
Curated resource library & partner perks	❌	✅

Professional All Access Pass Bonus

Join a dedicated lived experience workshop and be among the first to access our upcoming training: Lived Experience in MDMA Therapy for PTSD.

Clinical and scientific speakers

Join leading researchers and clinicians in psychedelic science as they share insights on integrating lived experience to improve clinical trials, therapist training, and treatment outcomes.

Bessel van der Kolk, MD

Psychiatrist, author of The Body Keeps the Score, and principal investigator for MDMA-assisted therapy for PTSD trials (U.S.)

Rosalind Watts, PhD

Clinical psychologist, ACER Integration founder, and former psilocybin clinical lead at Imperial College London (UK)

Michael Mithoefer, MD

Psychiatrist, clinical researcher, and medical monitor for MDMA-assisted psychotherapy for PTSD clinical trials (U.S.)

Marcela Ot’alora, MFA

Therapist, lead trainer, supervisor, and principal investigator for MDMA-assisted therapy for PTSD clinical trials (U.S.)

Bruce Poulter, RN, MPH

Therapist, lead trainer, supervisor, and sub-investigator for MDMA-assisted therapy for PTSD clinical trials (U.S.)

Corine de Boer, MD, PhD

Pediatrician, clinical researcher, former medical lead at Lykos/MAPS PBC, and founder & CEO at Tulip Medical Consulting (U.S.)

Matthew Johnson, PhD

Psychedelic researcher, experimental psychologist, senior investigator, and professor at Johns Hopkins School of Medicine (U.S.)

Monnica Williams, PhD

Clinical psychologist, researcher, and professor in the School of Psychology at University of Ottawa (Canada)

Jonathan Dickinson

Psychologist, renowned Ibogaine expert, published researcher, and CEO & co-founder at Ambio Life Sciences (Mexico/Canada)

Janis Phelps, PhD

Clinical psychologist, founder and director of the CIIS Center for Psychedelic Therapies and Research (U.S.)

Sandeep Nayak, MD

Psychiatrist, psilocybin clinical researcher, and associate professor at Johns Hopkins University (U.S.)

Sara Reed, MS

Marriage and family therapist, lead psychedelic clinical trial therapist at Imperial College London (UK)

Paul Liknaitzky, PhD

Psychologist, clinical researcher and head of Clinical Psychedelic Lab at Monash University (Australia)

Devon Christie, MD

Family physician and therapeutic counsellor, investigator for Phase 3 MDMA-assisted therapy for PTSD trials (Canada)

Manesh Girn, PhD

Neuroscientist, researcher at UCSF working with Robin Carhart-Harris, PhD on the impact of psychedelics on mental health (U.S.)

Stephanie Stewart, MD

Psychiatrist, board member of Chacruna Institute, former chief resident of psychiatry at Cedars-Sinai Medical Center (U.S.)

Chris Stauffer, MD

Psychiatrist and addiction medicine specialist, group MDMA therapy investigator for veterans with PTSD (U.S.)

Simon Ruffell, MD, PhD

Psychiatrist, research psychologist with PhD in ayahuasca and mental health, lecturer at the University of Exeter (UK)

Joost Breeksema, PhD

Qualitative researcher in psychedelic trials and executive director of the OPEN Foundation (Netherlands)

Pamela Kryskow, MD

Physician, board member of the Psychedelic Association of Canada and medical lead at the Roots to Thrive (Canada)

Houman Farzin, MD

Palliative care physician and psychedelic therapist specializing in psilocybin therapy for terminal illness (Canada)

Julia King Olivier, MD

Psychiatrist, psychedelic therapist, and founder of the Compassionate Care Center in Geneva (Switzerland)

Simon Amar, MD

Psychiatrist, investigator for MDMA therapy for PTSD trials (Canada) and psilocybin for anxiety trials (Australia)

Shoshana Ward, RTC

Therapist specializing in medicine assisted therapy, clinic director & co-founder at Centre for Medicine Assisted Therapy (Canada)

Bill Brennan, PhD

Psychologist, clinical researcher, psychedelic educator, author, and supervisor to therapists on clinical trials (U.S.)

Chloé Pronovost-Morgan, MD, MSc

Psychiatry resident and lead author on Delphi study for reporting of setting in psychedelic trials (Canada)

Will Barone, Psy.D

Clinical psychologist and qualitative researcher in MDMA therapy for terminal illness and studies with psilocybin & ketamine (U.S.)

Lived experience speakers

Hear from former patients and trial participants in treatments with MDMA, Psilocybin, LSD, Ketamine, 5-MeO-DMT, Ibogaine and other psychoactive substances. Their stories offer powerful insights to improve research design, therapist training, and future treatment outcomes.

Why aren’t all lived experiences represented? Find out why here.

Pedram Dara

MDMA-assisted psychotherapy for PTSD, Phase 2 trial participant (open-label, Canada, 2019)

Becca Kacanda

MDMA-assisted psychotherapy for PTSD, Phase 3 trial participant (active arm, U.S., 2022)

Mark Keller

Ibogaine & 5-MeO-DMT for PTSD, addiction, and BIND clinical treatment patient (Mexico / U.S. 2021-22)

Juliana Mulligan, LMSW

Ibogaine for opioid dependency, clinical treatment patient & therapist (U.S. 2011)

Ian Roullier

Psilocybin for depression pilot study and phase 2 clinical trials participant (UK, 2015 and 2019)

Maya Albert

Psilocybin-assisted therapy for anorexia nervosa, Phase 1 trial participant (open-label, U.S., 2021)

Daniel Friedrich

U.S. veteran, peer support and study facilitator for MDMA and psilocybin studies (U.S.)

Kim Fluxgold

Psilocybin for treatment-resistant depression, clinical trial participant (open-label, Canada, 2022)

Leonie Schneider

Psilocybin and DMT for depression clinical trials participant (UK, 2019 and 2022)

Ian Cook

Ketamine therapy for bipolar I, depression, and anxiety, clinical treatment patient (U.S., 2022)

Maryam Jabir

Psilocybin for treatment-resistant depression, Phase 2 clinical trial participant (UK, 2021)

Andrea Siclari

LSD-assisted therapy for life-threatening illness, compassionate use patient (Switzerland, 2020)

Lauren Macdonald, MD

Legal psilocybin retreat for terminal cancer participant, psychiatrist, trial doctor & therapist (UK, 2018)

Cedric Codron

SPRAVATO® (esketamine) for depression, clinical treatment patient (Belgium, 2022)

Florence Moureaux

Psilocybin-assisted therapy for terminal cancer, special access program patient (Canada, 2021)

Announcing Soon

LSD-assisted therapy for mood disorders, compassionate use patient (Switzerland, 2024)

Brad Gagnon

MDMA-assisted therapy for PTSD, special access program patient (Canada, 2024)

Kathy Neustadt

MDMA-assisted therapy for PTSD, Phase 3 trial participant (placebo only, U.S., 2021)

Ron Bowman

MDMA-assisted psychotherapy for PTSD, Phase 3 trial participant (active arm, U.S., 2020)

Leonie McCoy

Psilocybin-assisted therapy for generalized anxiety disorder, clinical trial participant (Australia, 2022)

Kerrilee Barrett

Psychoactive substance for PTSD Phase 2 clinical trial participant (double blinded then open label, UK, 2024)

Daryna Skybina

Psilocybin-assisted therapy for advanced cancer trial participant & qualifying therapist (Canada, 2025)

Announcing Soon

MDMA-assisted massed exposure therapy for PTSD, Phase 2 trial participant (open-label, U.S., 2025)

Heather Spiegel

Psilocybin for treatment-resistant depression, clinical trial participant (open-label, Canada, 2022)

Unlock the full summit experience today!

The All Access Pass was carefully prepared for you to get the most value out of the summit and get maximum results, with minimal time commitment. And if you upgrade today, you'll save as an early supporter.

Community
All Access Pass

Perfect for general attendees seeking full summit access at the lowest possible rate.

$67 USD Save $80

Regular price: $147

UPGRADE NOW

Professional
All Access Pass

Designed for therapists, physicians, researchers, coaches, & practitioners.

$97 USD Save $100

Regular price: $197

UPGRADE NOW

To pay, use the same email you registered with for the Free Live Pass.

Support a nonprofit mission

Upgrading to All Access Pass helps launch the

Psychedelic Lived Experiences Association (PLEA)

a new nonprofit advancing lived experience in

psychedelic research, treatment, and policy.

Need a scholarship?

APPLY NOW

Frequently Asked Questions

When does the limited-time deal on All Access Pass end?

The Community All Access pass is just $67 before it goes up to $97 (after Oct 1), $127 (after Nov 1), then $147 (after Nov 21). The Professional All Access pass is just $97 before it goes up to $137 (after Oct 1), $177 (after Nov 1), then $197 (after Nov 21). Prices increase as the summit approaches and our operational costs rise with more attendees. We suggest locking in the lowest price before rates go up! Price increases happen without notice. With no sponsorship funding, we personally cover all expenses. The best deal is always now!

What's the difference between Community and Professional pass?

The Community All Access Pass is for general attendees seeking full summit access at the lowest rate ever. It provides full access to all recordings, live panels, community, resources, and other exclusive content. However, the Professional all Access Pass is designed for therapists, physicians, researchers, coaches, and practitioners., you'll get everything from the Community Pass plus access to a hands-on group workshop and early access to our new training (lived experience in MDMA therapy for PTSD). Your purchase directly supports our mission, funds our peer support groups, and helps subsidize scholarships for others. Thank you!

Are there group discounts available?

Yes! Joining together is more fun. To inquire about group discounts, send us an email. >>> contact@psychedeliclivedexperiences.com

How will I receive what's included in the All Access Pass?

After you place your order, you'll instantly receive an email with all the summit details. Some resources, like the curated library, workshop registration, and partner perks, will be available before the event. Others, including session recordings, audio downloads, and the live expert panels, will be released during and/or after the summit. You'll receive everything via email, so you can access it anytime. Be sure to save the email for quick access or download the materials to your device for convenience.

How can I watch or listen to the session recordings?

You can watch the session recordings via your web browser (such as Chrome, Safari, Edge) on your computer, phone or tablet. Or you can download the audio versions to any of your devices and listen on the go! When you upgrade to an All Access Pass, you'll get full access to these materials as they become available from now until after the summit days.

Can I buy the All Access Pass as a gift? How do I contact you?

Of course! You can make the purchase with your own email address and then contact us to transfer it to the person you want to gift it to. >>> contact@psychedeliclivedexperiences.com